in vitro ATAD2 inhibitor - AstraZeneca

in vitro ATAD2 inhibitor

Preclinical, oncology

from 1.8 million compound HTS and opt.

J. Med. Chem.


Context. AZ13824374 (AstraZeneca) is an in vitro ATAD2 inhibitor. Reviewer and nominator Julien Lefranc says, “several ATAD2 probes have been published in the past (including GSK 8814, GSCK388, and…

 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.